File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Heterogeneity within the PF-EPN-B ependymoma subgroup

TitleHeterogeneity within the PF-EPN-B ependymoma subgroup
Authors
KeywordsClustering
Ependymoma
PFA
PFB
Posterior fossa
Subgrouping
Issue Date2018
Citation
Acta Neuropathologica, 2018, v. 136, n. 2, p. 227-237 How to Cite?
AbstractPosterior fossa ependymoma comprise three distinct molecular variants, termed PF-EPN-A (PFA), PF-EPN-B (PFB), and PF-EPN-SE (subependymoma). Clinically, they are very disparate and PFB tumors are currently being considered for a trial of radiation avoidance. However, to move forward, unraveling the heterogeneity within PFB would be highly desirable. To discern the molecular heterogeneity within PFB, we performed an integrated analysis consisting of DNA methylation profiling, copy-number profiling, gene expression profiling, and clinical correlation across a cohort of 212 primary posterior fossa PFB tumors. Unsupervised spectral clustering and t-SNE analysis of genome-wide methylation data revealed five distinct subtypes of PFB tumors, termed PFB1-5, with distinct demographics, copy-number alterations, and gene expression profiles. All PFB subtypes were distinct from PFA and posterior fossa subependymomas. Of the five subtypes, PFB4 and PFB5 are more discrete, consisting of younger and older patients, respectively, with a strong female-gender enrichment in PFB5 (age: p = 0.011, gender: p = 0.04). Broad copy-number aberrations were common; however, many events such as chromosome 2 loss, 5 gain, and 17 loss were enriched in specific subtypes and 1q gain was enriched in PFB1. Late relapses were common across all five subtypes, but deaths were uncommon and present in only two subtypes (PFB1 and PFB3). Unlike the case in PFA ependymoma, 1q gain was not a robust marker of poor progression-free survival; however, chromosome 13q loss may represent a novel marker for risk stratification across the spectrum of PFB subtypes. Similar to PFA ependymoma, there exists a significant intertumoral heterogeneity within PFB, with distinct molecular subtypes identified. Even when accounting for this heterogeneity, extent of resection remains the strongest predictor of poor outcome. However, this biological heterogeneity must be accounted for in future preclinical modeling and personalized therapies.
Persistent Identifierhttp://hdl.handle.net/10722/313944
ISSN
2023 Impact Factor: 9.3
2023 SCImago Journal Rankings: 4.720
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorCavalli, Florence M.G.-
dc.contributor.authorHübner, Jens Martin-
dc.contributor.authorSharma, Tanvi-
dc.contributor.authorLuu, Betty-
dc.contributor.authorSill, Martin-
dc.contributor.authorZapotocky, Michal-
dc.contributor.authorMack, Stephen C.-
dc.contributor.authorWitt, Hendrik-
dc.contributor.authorLin, Tong-
dc.contributor.authorShih, David J.H.-
dc.contributor.authorHo, Ben-
dc.contributor.authorSanti, Mariarita-
dc.contributor.authorEmery, Lyndsey-
dc.contributor.authorHukin, Juliette-
dc.contributor.authorDunham, Christopher-
dc.contributor.authorMcLendon, Roger E.-
dc.contributor.authorLipp, Eric S.-
dc.contributor.authorGururangan, Sridharan-
dc.contributor.authorGrossbach, Andrew-
dc.contributor.authorFrench, Pim-
dc.contributor.authorKros, Johan M.-
dc.contributor.authorvan Veelen, Marie Lise C.-
dc.contributor.authorRao, Amulya A.Nageswara-
dc.contributor.authorGiannini, Caterina-
dc.contributor.authorLeary, Sarah-
dc.contributor.authorJung, Shin-
dc.contributor.authorFaria, Claudia C.-
dc.contributor.authorMora, Jaume-
dc.contributor.authorSchüller, Ulrich-
dc.contributor.authorAlonso, Marta M.-
dc.contributor.authorChan, Jennifer A.-
dc.contributor.authorKlekner, Almos-
dc.contributor.authorChambless, Lola B.-
dc.contributor.authorHwang, Eugene I.-
dc.contributor.authorMassimino, Maura-
dc.contributor.authorEberhart, Charles G.-
dc.contributor.authorKarajannis, Matthias A.-
dc.contributor.authorLu, Benjamin-
dc.contributor.authorLiau, Linda M.-
dc.contributor.authorZollo, Massimo-
dc.contributor.authorFerrucci, Veronica-
dc.contributor.authorCarlotti, Carlos-
dc.contributor.authorTirapelli, Daniela P.C.-
dc.contributor.authorTabori, Uri-
dc.contributor.authorBouffet, Eric-
dc.contributor.authorRyzhova, Marina-
dc.contributor.authorEllison, David W.-
dc.contributor.authorMerchant, Thomas E.-
dc.contributor.authorGilbert, Mark R.-
dc.contributor.authorArmstrong, Terri S.-
dc.contributor.authorKorshunov, Andrey-
dc.contributor.authorPfister, Stefan M.-
dc.contributor.authorTaylor, Michael D.-
dc.contributor.authorAldape, Kenneth-
dc.contributor.authorPajtler, Kristian W.-
dc.contributor.authorKool, Marcel-
dc.contributor.authorRamaswamy, Vijay-
dc.date.accessioned2022-07-06T11:28:33Z-
dc.date.available2022-07-06T11:28:33Z-
dc.date.issued2018-
dc.identifier.citationActa Neuropathologica, 2018, v. 136, n. 2, p. 227-237-
dc.identifier.issn0001-6322-
dc.identifier.urihttp://hdl.handle.net/10722/313944-
dc.description.abstractPosterior fossa ependymoma comprise three distinct molecular variants, termed PF-EPN-A (PFA), PF-EPN-B (PFB), and PF-EPN-SE (subependymoma). Clinically, they are very disparate and PFB tumors are currently being considered for a trial of radiation avoidance. However, to move forward, unraveling the heterogeneity within PFB would be highly desirable. To discern the molecular heterogeneity within PFB, we performed an integrated analysis consisting of DNA methylation profiling, copy-number profiling, gene expression profiling, and clinical correlation across a cohort of 212 primary posterior fossa PFB tumors. Unsupervised spectral clustering and t-SNE analysis of genome-wide methylation data revealed five distinct subtypes of PFB tumors, termed PFB1-5, with distinct demographics, copy-number alterations, and gene expression profiles. All PFB subtypes were distinct from PFA and posterior fossa subependymomas. Of the five subtypes, PFB4 and PFB5 are more discrete, consisting of younger and older patients, respectively, with a strong female-gender enrichment in PFB5 (age: p = 0.011, gender: p = 0.04). Broad copy-number aberrations were common; however, many events such as chromosome 2 loss, 5 gain, and 17 loss were enriched in specific subtypes and 1q gain was enriched in PFB1. Late relapses were common across all five subtypes, but deaths were uncommon and present in only two subtypes (PFB1 and PFB3). Unlike the case in PFA ependymoma, 1q gain was not a robust marker of poor progression-free survival; however, chromosome 13q loss may represent a novel marker for risk stratification across the spectrum of PFB subtypes. Similar to PFA ependymoma, there exists a significant intertumoral heterogeneity within PFB, with distinct molecular subtypes identified. Even when accounting for this heterogeneity, extent of resection remains the strongest predictor of poor outcome. However, this biological heterogeneity must be accounted for in future preclinical modeling and personalized therapies.-
dc.languageeng-
dc.relation.ispartofActa Neuropathologica-
dc.subjectClustering-
dc.subjectEpendymoma-
dc.subjectPFA-
dc.subjectPFB-
dc.subjectPosterior fossa-
dc.subjectSubgrouping-
dc.titleHeterogeneity within the PF-EPN-B ependymoma subgroup-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s00401-018-1888-x-
dc.identifier.pmid30019219-
dc.identifier.pmcidPMC6373486-
dc.identifier.scopuseid_2-s2.0-85049943373-
dc.identifier.volume136-
dc.identifier.issue2-
dc.identifier.spage227-
dc.identifier.epage237-
dc.identifier.eissn1432-0533-
dc.identifier.isiWOS:000440074600004-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats